Azathioprine use in patients with Inflammatory Bowel Disease. Adherence to treatment and adverse events. A single center experience

被引:0
|
作者
Viazis, N. [1 ]
Vlachogiannakos, J. [1 ]
Georgiadis, D. [1 ]
Keyoglou, A. [1 ]
Vasianopoulou, P. [1 ]
Markoutsaki, Th. [1 ]
Komninou, E. [1 ]
Markoglou, K. [1 ]
Gouma, P. [1 ]
Karamanolis, D. G. [1 ]
机构
[1] Evangelismos Med Ctr, Dept Gastroenterol 2, Athens, Greece
来源
ANNALS OF GASTROENTEROLOGY | 2009年 / 22卷 / 03期
关键词
Azathioprine; inflammatory bowel disease; adverse events; patients' adherence to treatment;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Azathioprine is frequently used in achieving and maintaining remission in patients with inflammatory bowel disease. Aim: We performed a prospective study on patients with inflammatory bowel disease receiving azathioprine who were followed up at our hospital, in order to record their adherence to treatment and the frequency of adverse events. Methods: Fifty seven patients (23 males, 34 females, mean age 40.3 years) were included in our analysis. Thirty patients had Crohn's disease and 27 patients were diagnosed with ulcerative colitis. All patients were followed up at our outpatient's clinic with complete blood counts, liver enzymes and pancreatic enzyme levels monitored at weeks 1, 2, 4, 8 and 12 after initiation of azathioprine administration, with subsequent testing every 12 weeks for the duration of azathioprine treatment. Meanwhile, all patients, after 1 year of azathioprine administration, fulfilled a specialized questionnaire in order to determine their adherence to treatment. Results: The most common adverse event was a rise in amylase levels occurring in 3 of our patients (5.3%). Leukopenia requiring dose reduction (leukocyte count < 3.5 x 10(9)) was seen in 2 patients (3.5%), while severe leukopenia (leukocyte count < 2.5 x 10(9)) was seen in only 1 patient (1.7%). In this patient leukocyte count returned to normal after azathioprine discontinuation. Hepatotoxicity was less common occurring in 1.7% of our study population (1 patient only). Nonadherence rate was 24.5% of the patients included. The only factor associated with a better adherence was a more complicated course of the disease(p=.02). Conclusions: Azathioprine use in patients with inflammatory bowel disease appears to be safe, with adverse events being reversible and occurring in a minority of those treated. An important proportion of patients with IBD admit to forgetting some doses of the prescribed medication in the setting of a specialized unit of a referral centre.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 50 条
  • [1] Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
    Chun, Ji Young
    Kang, Ben
    Lee, Yoo Min
    Lee, Soo Youn
    Kim, Mi Jin
    Choe, Yon Ho
    [J]. PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2013, 16 (03) : 171 - 177
  • [2] Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
    Kim, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S280 - S281
  • [3] Asian experience of azathioprine treatment in inflammatory bowel disease patients
    Thia, T. J. K.
    Ling, K. L.
    Ooi, C. J.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A198 - A198
  • [4] Audit of longterm azathioprine use in inflammatory bowel disease.
    Chew, C
    Evans, C
    Curry, G
    Penney, C
    Cochran, K
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1337 - A1337
  • [5] Adverse effects of azathioprine in the treatment of inflammatory bowel disease
    Martínez, F
    Nos, P
    Pastor, M
    Garrigues, V
    Ponce, J
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2001, 93 (12) : 774 - 778
  • [6] Therapeutic adherence in patients with inflammatory bowel disease.
    Azucena, C.
    Nallely, B.
    Jesus, Y. -F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S276 - S277
  • [7] Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease
    Sternthal, Michael B.
    Murphy, Seamus J.
    George, James
    Kornbluth, Asher
    Lichtiger, Simon
    Present, Daniel H.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04): : 937 - 943
  • [8] Adverse effects of azathioprine in patients with inflammatory bowel disease (IBD)
    Ramirez de la Piscina, P.
    Estrada, S.
    Duca, I.
    Spicakova, K.
    Ganchegui, I.
    Calderon, M. D. R.
    Campos, A.
    Salvador, M.
    Delgado, E.
    Lopez Barbarin, J. M.
    Garcia Campos, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S309 - S309
  • [9] Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
    Erdogan, Cagdas
    Yesil, Bayram
    Bacaksiz, Ferhat
    Ari, Derya
    Gokbulut, Volkan
    Yuksel, Mahmut
    Ozin, Yasemin Ozderin
    Kayacetin, Ertugrul
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (10): : 831 - 837
  • [10] Inflammatory bowel disease. Experience in 316 patients
    Simian, Daniela
    Estay, Camila
    Lubascher, Jaime
    Acuna, Raul
    Kronberg, Udo
    Figueroa, Carolina
    Brahm, Javier
    Silva, Guillermo
    Lopez-Koestner, Francisco
    Wainstein, Claudio
    Larach, Andres
    Larach, Jorge
    Quera, Rodrigo
    [J]. REVISTA MEDICA DE CHILE, 2014, 142 (08) : 1006 - 1013